910129-15-6

Basic information

• Product Name: 5'-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine
• Synonyms: 5'-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine;Capecitabine iMpurity E;Cytidine, 5'-deoxy-5-fluoro-N-[(2-Methylbutoxy)carbonyl]-;5'-Deoxy-5-fluoro-N4-(2-methyl-1-butyloxycarbonyl)cytidine;Capecitabine 2-Methylbutyloxy Impurity;5'-Deoxy-5-fluoro-N4-[(2-methylbutoxy)carbonyl]-cytidine;2-Methylbutyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate;Capecitabine EP Impurity D
• CAS NO: 910129-15-6
• Molecular Formula: C15H22FN3O6
• Molecular Weight: 359.3500832
• Product Categories: Bases & Related Reagents;Intermediates;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 910129-15-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 62-64°C
• Appearance: /
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 5'-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine(910129-15-6)
• EPA Substance Registry System: 5'-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine(910129-15-6)

Safety Data

• Hazardous Substances Data: 910129-15-6(Hazardous Substances Data)

Usage

Description

5'-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine, also known as Capecitabine EP Impurity D, is a Capecitabine analog with demonstrated antitumor activity. It is an off-white solid and is used in the pharmaceutical industry for its potential therapeutic effects.
Used in Pharmaceutical Industry:
5'-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine is used as an antitumor agent for its potential to combat cancer cells. As a Capecitabine analog, it is employed in research and development for cancer treatment, aiming to provide an alternative or complementary approach to existing therapies.

Upstream product

• 1341231-51-3 C₁₉H₂₆FN₃O₈ 
• 137-32-6 (+/-)-2-methyl-1-butanol 
• 100980-71-0 2-methyl-butyl chloroformate 
• 161599-46-8 (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-5-methyl-tetrahydrofuran-3,4-diyl diacetate 

Relevant articles and documents

Preparation method for high-yield capecitabine impurity F

The invention relates to a preparation method for a high-yield capecitabine impurity F. The preparation method comprises the following steps that (a) 2-methyl-1-pentanol, tetrahydrofuran and triethylamine are added into a reaction vessel, after nitrogen replacement is carried out, cooling is carried out to reach the temperature of less than or equal to 0 DEG C, a triphosgene tetrahydrofuran solution is dropwise added, heating is carried out for reaction, filtering is carried out so as to obtain a filtrate, and spin-drying is carried out so as to obtain a first mixture; (b) potassium carbonate,2',3'-di-O-acetyl-5'-deoxy-5-fulurocytidine and acetone are added into another reaction vessel, after nitrogen replacement is carried out, an acetone solution of the first mixture is dropwise added for reaction, and filtering is carried out so as to obtain a reaction solution of a second mixture; and (c) the reaction solution of the second mixture is cooled to be less than or equal to -10 DEG C,the pH value is adjusted to be alkaline for reaction, then the pH value is adjusted to be neutral, the acetone is spin-dried, extraction is carried out on an aqueous phase multiple times by using ethyl acetate, organic phases are combined, drying is carried out, then spin-drying is carried out, and column chromatography is carried out. The product obtained through the method has the advantages ofbeing high in purity and high in yield.

Preparation method of capecitabine impurity F

The invention relates to a preparation method of a capecitabine impurity F. The preparation method comprises the following steps: (a) adding 2-methyl-1-butanol, tetrahydrofuran, triethylamine, nanometer titania and nano-iron oxide into a reaction container, performing nitrogen displacement, cooling to a temperature of less than or equal to 0 DEG C, dropwise adding a tetrahydrofuran solution of triphosgene, reacting under UV-irradiation, filtering to obtain filtrate, and performing spin drying so as to obtain a first mixture; (b) adding potassium carbonate, 2', 3'-bi-O-acetyl-5'-deoxo-5-fluorocytidine and acetone into another reaction container, dropwise adding an acetone solution of the first mixture to react after nitrogen displacement, and filtering to obtain a reaction solution of a second mixture; and (c) cooling the reaction solution of the second mixture to a temperature of less than or equal to 10 DEG C below zero, regulating the pH value to be alkaline, and reacting. Therefore,the product purity is improved on the premise of shortening the reaction time, and the process steps are simplified.